netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Carboplatin found 11 matches
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Carboplatin Malignant disease and immunosuppression - Platinum compounds - 08.01.05
  Amivantamab  (Rybrevant®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Atezolizumab Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Paclitaxel - Albumin Bound Formulation  (Abraxane®) Malignant disease and immunosuppression - Taxanes - 08.01.05
  Cytotoxic Drug Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA1041: Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (08.01.05)
link in drug section NICE TA1092: Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (08.01.05)
link in drug section NICE TA1158: Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (08.01.05)
link in drug section NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)


 
netFormulary